Comparative Pharmacology
Head-to-head clinical analysis: KARIVA versus LOESTRIN 21 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KARIVA versus LOESTRIN 21 1 5 30.
KARIVA vs LOESTRIN 21 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits gonadotropin release, suppressing ovulation, altering cervical mucus to impede sperm penetration, and changing endometrial receptivity.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial morphology.
One tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours; in renal impairment (CrCl <30 mL/min), half-life may extend to 8-10 hours, requiring dose adjustment.
Ethinyl estradiol: ~12-14 h; Norethindrone: ~5-12 h. Steady-state achieved in ~5-10 days.
Approximately 55% renal (30% as unchanged drug, 25% as metabolites) and 45% fecal (via biliary elimination).
Primarily hepatic metabolism; ~40-60% renal, 20-30% biliary/fecal.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive